Mental Health DailyResearch. Evidence. Perspective.Published research on Antipsychotics.
Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will e…
Read articleIt is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population. There are many different types…
Read articleInvega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interac…
Read articleInvega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega S…
Read articleFanapt (Iloperidone) is an antipsychotic that was approved in 2009 for the treatment of schizophrenia. It functions similar to most current-market atypical antipsychotics in that it acts as …
Read articleFanapt (Iloperidone) is an atypical antipsychotic that was approved by the FDA on May 6, 2009 for the treatment of schizophrenia. The drug is thought to have been synthesized in the 1990s, d…
Read articleSaphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A ser…
Read article